$AKBA

Akebia Therapeutics (AKBA) reported Q3 revenue of $36.9M, down from $58.8M YoY, with a net loss of $14.4M. The company expects Vafseo therapy costs to range between $1,000-$1,500 annually post-TDAPA. AKBA is negotiating contracts and aims for Vafseo to become a standard of care, potentially treating 200,000-250,000 patients. Clinical trials showed Vafseo's active ingredient, vadadustat, reduced hospitalizations by 10% compared to ESAs.

Akebia Therapeutics, Inc. (AKBA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025 Q3 2026 Vafseo® (v

Akebia Therapeutics reported that its VOCAL trial met the primary endpoint, showing non-inferiority of vadadustat to ESA in maintaining hemoglobin levels in chronic kidney disease patients on hemodialysis. The trial enrolled 353 patients, with similar adverse event rates between treatments. Vadadustat is FDA-approved for once-daily use but is being studied for a three-times-weekly dosing regimen.

Akebia Therapeutics (AKBA) announced that vadadustat, its kidney anemia drug, reduced hospitalization rates by 10% compared to standard treatment in dialysis patients, according to the VOICE trial presented at ASN Kidney Week 2026. The trial, sponsored by U.S. Renal Care, showed fewer serious adverse events and better hemoglobin control with vadadustat. Vafseo, the brand name for vadadustat, was approved by the FDA in March 2024 for anemia treatment in dialysis patients.

Akebia Therapeutics reported that the VOICE trial showed vadadustat TIW was superior to ESA in dialysis patients, with lower mortality, fewer hospitalizations, and fewer serious adverse events. The trial involved 2,116 patients and showed statistical significance (p=0.0016).

Akebia Therapeutics (AKBA) received a notice from Nasdaq for falling below the $1.00 minimum bid price for 30 days, violating listing rules. The company has until April 19, 2027, to comply, with a potential extension if other conditions are met. The notice does not immediately affect its listing.

Akebia Therapeutics' Chief Commercial Officer Nicholas Grund will resign on November 6, 2026, and serve as a consultant until April 30, 2027, according to an SEC filing.

Akebia Therapeutics, Inc. (AKBA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 7, 2026, Nicholas Grund, Senior Vice President and Chief Commercial Officer of Akebia Therapeutics, Inc. (the “

Akebia Therapeutics (AKBA) dosed the first patient in a Phase 2 trial of ebribafusp for rare kidney diseases. The trial will enroll up to 30 patients and evaluate safety, proteinuria, and kidney function. Ebribafusp aims to inhibit complement activation in kidney tissue. Initial data is expected in 2027. AKBA's stock is currently at $0.90, down 4.87%.

Akebia Therapeutics, Inc. (AKBA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million; more than 10,500 p atients now on therapy Advancement of rare kidney disease pipeline continues with ini